Enveric Biosciences financials
$1.45−1.36%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$3.0M | -$1.6M | -$2.2M | -$1.9M | -$2.5M | -$2.2M | -$3.2M | -$2.1M | -$1.9M | -$2.5M | -$2.4M | -$3.4M |
| Net income | -$3.0M | -$1.6M | -$4.0M | -$3.4M | -$2.5M | -$2.2M | -$3.2M | -$2.1M | -$1.9M | -$2.5M | -$3.4M | -$2.8M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.76 | $-1.08 | $-6.13 | $-10.81 | $-11.65 | $-14.58 | $-31.79 | $-43.10 | $-44.64 | $-110.52 | $-270.58 | $-234.00 |
| EBITDA | -$3.0M | -$1.6M | -$2.2M | -$1.8M | -$2.5M | -$2.1M | -$3.2M | -$2.0M | -$1.8M | -$2.4M | -$2.3M | -$3.4M |
| Operating cash flow | -$2.4M | -$2.3M | -$1.8M | -$2.1M | -$1.9M | -$2.4M | -$1.3M | -$927.1K | -$2.9M | -$2.6M | -$1.8M | -$2.7M |
| Free cash flow | -$2.4M | -$2.3M | -$1.8M | -$2.1M | -$1.9M | -$2.4M | -$1.3M | -$927.1K | -$2.9M | -$2.6M | -$1.8M | -$2.7M |
| Diluted shares | 4.0M | 1.5M | 0.7M | 0.3M | 0.2M | 0.1M | 0.1M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.3M | $4.9M | $4.7M | $3.8M | $2.8M | $4.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $8.9M | $5.5M | $5.1M | $4.4M | $3.5M | $5.1M |
| Total liabilities | $861.5K | $460.7K | $918.4K | $905.9K | $1.4M | $1.2M |
| Shareholders' equity | $8.1M | $5.1M | $4.2M | $3.5M | $2.2M | $3.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology